CGM After Discharge From Hospital

Continuous Glucose Monitoring for Post-discharge Diabetes Management

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07510386

Enrollment

Registered

2026-04-03

Start date

2026-09-30

Completion date

2026-11-01

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Steroid-induced Diabetes, Type 2 Diabetes

Keywords

discharge, CGM

Brief summary

This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.

Interventions

DEVICELibre 3 Plus continuous glucose monitoring (CGM) system

Use of unmasked CGM after discharge

DEVICEBlinded Continuous Glucose Monitoring

Masked CGM

BEHAVIORALFinger stick

Self-monitoring blood glucose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

randomized control trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult 18 years or older. * Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge.

Exclusion criteria

* Type 1 diabetes * Plan for discharge to rehabilitation/skilled nursing/hospice facility * Contra-indication to sensor placement * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
time in range 70-180 mg/dl	Day 20-30	percent time in range for last 10 days of study

Secondary

Measure	Time frame	Description
30 day time in range	Day 30	Overall 30 day time in range
Percent time >180mg/dL	Day 30	percent time in range on day 30
Percent time >250mg/dL	Day 30	percent time in range on day 30
Percent time <70mg/dL	Day 30	percent time in range on day 30
Percent time <54mg/dL	Day 30	percent time in range on day 30

Countries

United States

Contacts

CONTACTSophie Baum

sophie.baum@mssm.edu212-241-7173

PRINCIPAL_INVESTIGATORGrenye O'Malley, MD

Icahn School of Medicine at Mount Sinai

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026